GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Gross-Profit-to-Asset %

Vectus Biosystems (ASX:VBS) Gross-Profit-to-Asset % : 0.05% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Vectus Biosystems's annualized Gross Profit for the quarter that ended in Dec. 2023 was A$0.00 Mil. Vectus Biosystems's average Total Assets over the quarter that ended in Dec. 2023 was A$3.92 Mil. Therefore, Vectus Biosystems's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.05%.


Vectus Biosystems Gross-Profit-to-Asset % Historical Data

The historical data trend for Vectus Biosystems's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Gross-Profit-to-Asset % Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial - - - - -

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.37 - 0.05

Competitive Comparison of Vectus Biosystems's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Vectus Biosystems's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Gross-Profit-to-Asset % falls into.



Vectus Biosystems Gross-Profit-to-Asset % Calculation

Vectus Biosystems's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=0/( (3.936+4.63)/ 2 )
=0/4.283
=0.00 %

Vectus Biosystems's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0.002/( (4.63+3.207)/ 2 )
=0.002/3.9185
=0.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Vectus Biosystems Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines